Public payers cover academic CAR-T at cost as a benchmark for commercial prices
Hospitals in Spain make their own CAR-T for a third of the commercial price. Paying for such products at cost gives health systems a lever in negotiating with companies.
ARI-0001 and similar academic products are reimbursed in Spain under the hospital exemption at a fraction of commercial list prices, and published outcomes are comparable in matched populations. The proposal is for other public payers to establish explicit coverage of academic point-of-care CAR-T at audited cost plus a fixed margin, publish that cost, and use it as the reference price in negotiations for commercial products in the same indication, creating a competitive benchmark that does not otherwise exist for single-source therapies.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
Pages like this
not linked directly; found by shared links- IdeaPay for one-time curative therapies as an annuity that stops at relapse
Shares Prices and value, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaA neutral slot exchange so unused CAR-T manufacturing slots go to the next patient
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaPublic reference standards and potency assays for CAR-T so every lab measures alike
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaTwo-day CAR-T manufacture paired with rapid release tests that regulators accept
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaAn open interoperability standard for closed automated cell-processing machines
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaMutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaFull refund for CAR-T if the patient has not responded at three months
Shares Prices and value, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.